Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Nov 15, 2026
TickeronGET DAILY SIGNALS
Huize Holding Limited (HUIZ): Weighing the Path to a +24% Move Toward $3.00

Huize Holding Limited (HUIZ): Weighing the Path to a +24% Move Toward $3.00

Key Takeaways

  • The central target of $3.00 is a fallback objective drawn from public discussion and technical levels, not an analyst consensus, because HUIZ has extremely thin and largely stale sell-side coverage.
  • With the latest verified close of $2.41, reaching $3.00 implies a move of roughly 24%—a substantial, but not extraordinary, upside.
  • The sparse analyst context shows a range from about $2.30 (Citigroup, Neutral, June 2025) to $3.50 (a Hold referenced by TipRanks in late 2025), with average estimates around $2.88 to $2.93—figures that are now outdated.
  • The strongest supports are improving fundamentals: H1 2026 net profit swung to RMB 25.3 million, gross written premiums grew roughly 30%, and international revenue is approaching half of the total.
  • The biggest risks are a micro-cap profile (~$24 million market cap), thin trading liquidity, a prior Nasdaq minimum-bid-price compliance notice, and minimal analyst sponsorship.
  • Valuation appears undemanding—a trailing P/E around 6 to 8, a price-to-sales ratio near 0.1, and a price-to-book ratio near 0.4—but those multiples reflect real risk.
  • For deeper context, review Huize's Major News and Today's Price Move, along with its Forecast and Earnings pages.
  • Explore Trending AI Robots for AI-driven tools that monitor changing market conditions.

Analyst Price Targets and Consensus View

Huize Holding Limited (HUIZ) is an American Depositary Receipt (ADR) for a China-based online insurance brokerage and insurtech platform. It is a micro-cap stock with very limited, largely dated analyst coverage, so it fails the standard test of having multiple credible, current price targets. Instead of forcing a fabricated consensus, the $3.00 target used here comes from identifiable public discussion and technical levels: a round-number psychological objective that sits modestly above the last reported average estimates (about $2.88 to $2.93) and below the 52-week high of $3.83.

For context only—never as the working target—the visible analyst trail is thin. Citigroup's Michelle Ma downgraded the stock to Neutral with a $2.30 target in June 2025, while a Hold with a $3.50 target was cited by TipRanks in late 2025. Those figures are stale and bracket the current price rather than offering a usable forward consensus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

The latest verified close is $2.41, giving Huize a market capitalization of roughly $24 million. Reaching $3.00 would require about a 24% gain—a substantial move for a low-liquidity micro-cap. The path would likely need two ingredients: sustained fundamental delivery and a recovery in investor sentiment that currently discounts Chinese small-cap and insurance-distribution risk heavily.

Huize reported a swing to RMB 25.3 million in net profit for the first half of 2026, with gross written premiums up about 30% and first-year premiums up roughly 49% year over year. International revenue—driven by Hong Kong, Singapore, and Vietnam—now approaches 50% of the total. If the company continues converting premium growth into profit, the valuation multiple could re-rate, but this is far from assured given the stock's thin float and institutional ownership near zero.

What Could Support a Move Toward the Target

  • Profitability inflection: Net profit improved sharply in H1 2026, and management points to AI-driven efficiency gains and improving expense ratios.
  • Premium momentum: Record GWP and FYP growth indicate robust underlying demand for long-term savings and protection products amid China's low-rate environment.
  • International diversification: Scaling Hong Kong, Singapore, and Vietnam operations reduces single-market concentration and supports revenue diversification.
  • Balance-sheet cushion: Cash and cash equivalents of roughly RMB 241 million, paired with high persistency ratios above 95%, provide a foundation that appears stronger than the sub-$25 million market cap implies.

What Could Prevent the Target From Being Reached

  • Thin liquidity and micro-cap status: Very low average daily volume and near-zero institutional ownership make sustained price advances difficult.
  • Compliance risk: Huize previously received a Nasdaq minimum-bid-price non-compliance notice, a reminder of the delisting and reverse-split risks facing sub-$1-adjacent listings.
  • China regulatory and macro exposure: Insurance distribution is subject to shifting regulation, and Chinese ADRs carry ongoing policy and delisting-related sentiment risk.
  • Cost and margin pressure: Historically, rising customer-acquisition and channel costs have compressed margins even when revenue grew.

Technical Levels and Market Structure

The 52-week range of $1.04 to $3.83 defines the meaningful technical landscape. The $3.83 prior high is a durable resistance level, while $3.00 acts as an intermediate psychological round-number level. On the downside, the $2.20–$2.40 zone has served as recent support, with the $1.04 low representing the deep cyclical floor. A sustained break above the low-to-mid $2.80s would be needed to put the $3.00 objective within reach, and $3.83 would be the next major hurdle beyond it. From what I see, tools like Tickeron’s AI Trend Prediction Engine can help spot these levels more systematically.

Time Horizon and What Investors Should Monitor

Analyst targets generally reflect a roughly 12-month horizon, but with coverage this thin and stale no reliable horizon can be assumed. The most relevant near-term catalyst is Huize's third-quarter 2026 results, expected around late November 2026. Investors should watch premium growth (GWP and FYP), net margin progression, international revenue share, any Nasdaq compliance updates, and whether any sell-side firm reinitiates coverage with a refreshed target. Changes in China's regulatory stance and broader sentiment toward Chinese ADRs would also matter.

AI Daily Buy/Sell Signals

One tool I find useful for stocks like this is Tickeron's AI Daily Buy/Sell Signals. It uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a thinly covered stock like HUIZ, where analyst updates are rare, such signal-driven tools can help traders discover opportunities, monitor positions, and identify shifting trends more efficiently than manual screening. Traders interested in data-driven timing can explore these signals alongside their own research.

Final Assessment

Whether Huize can reach $3.00 depends less on a published analyst consensus—which does not meaningfully exist today—and more on execution and sentiment. The roughly 24% required move is substantial but not extreme, and the company's improving profitability, premium momentum, and international expansion provide credible support. The obstacles are equally real: a sub-$25 million market cap, minimal liquidity, prior Nasdaq compliance warnings, and persistent discounting of Chinese micro-caps. The target is best understood as a technical and psychological benchmark rather than a forecast, and investors should watch the upcoming earnings report and any renewal of analyst coverage before drawing conclusions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: HUIZ

Contributor

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.


HUIZ's RSI Oscillator leaves overbought zone

The 10-day RSI Indicator for HUIZ moved out of overbought territory on October 23, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 instances where the indicator moved out of the overbought zone. In 19 of the 21 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 46 cases where HUIZ's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for HUIZ turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 44 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HUIZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

HUIZ broke above its upper Bollinger Band on November 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for HUIZ entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 13, 2026. You may want to consider a long position or call options on HUIZ as a result. In 70 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.

HUIZ moved above its 50-day moving average on October 16, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for HUIZ crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.

The 50-day moving average for HUIZ moved above the 200-day moving average on October 29, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +10.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where HUIZ advanced for three days, in 170 of 217 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.053) is normal, around the industry mean (2.681). P/E Ratio (1.140) is within average values for comparable stocks, (19.012). Projected Growth (PEG Ratio) (1.770) is also within normal values, averaging (8.322). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (0.061) is also within normal values, averaging (2.968).

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. HUIZ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 77 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HUIZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.

Notable companies

The most notable companies in this group are eHealth (NASDAQ:EHTH).

Industry description

Insurance brokers sell, solicit, or negotiate insurance for compensation. General insurance brokers mostly cater to insurances on car, house etc. (versus life). Brokers are also often instrumental in helping small employers find health insurance, particularly in more competitive markets. Additionally, brokers may also provide risk assessments, insurance consulting services, insurance-related regulatory and legislative update services. Some of the major names in this industry include Marsh & McLennan Companies, Inc., Aon plc and Verisk Analytics Inc.

Market Cap

The average market capitalization across the Insurance Brokers/Services Industry is 15.27B. The market cap for tickers in the group ranges from 3.03K to 97.74B. MRSH holds the highest valuation in this group at 97.74B. The lowest valued company is CUII at 3.03K.

High and low price notable news

The average weekly price growth across all stocks in the Insurance Brokers/Services Industry was 1%. For the same Industry, the average monthly price growth was 12%, and the average quarterly price growth was 18%. AIFU experienced the highest price growth at 25%, while GSHD experienced the biggest fall at -17%.

Volume

The average weekly volume growth across all stocks in the Insurance Brokers/Services Industry was 233%. For the same stocks of the Industry, the average monthly volume growth was 288% and the average quarterly volume growth was 138%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 71
Price Growth Rating: 49
SMR Rating: 72
Profit Risk Rating: 85
Seasonality Score: 2 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company, which engages in the provision of insurance brokerage services through online platform

Industry InsuranceBrokersServices

Industry
N/A
Address
Qianhai Financial Centre, Linhai Avenue
Phone
+86 75536899088
Employees
853
Web
https://www.huize.com
Interact to see
Advertisement
The central price target used here is $400 , roughly 35% above Alphabet's latest verified closing price of $295.77 (November 13, 2026). This target is the arithmetic mean of verified analyst price targets reviewed, not a single analyst's forecast; independent data providers report comparable consensus averages in the high-$390s to low-$400s.
Upcoming catalysts: Integration of advertising into AI Overviews and Gemini conversations, the scaling of Gemini 3 and newer models across Search and Cloud, and the commercial ramp of the $32 billion Wiz cloud-security acquisition could all shape sentiment into 2026. Strategic positioning: Alphabet's vertically integrated artificial intelligence (AI) stack — from custom TPU (Tensor Processing Unit) chips to the Gemini models to Google Cloud — supports a durable, cost-advantaged position in the AI build-out.
The TETH exchange-traded fund (ETF) is the 21Shares Ethereum Staking ETF, a spot Ethereum fund listed on Cboe BZX, and it does not carry conventional analyst price targets. The $14 objective used here is a technical milestone discussed in public market commentary — roughly the zone where Ethereum could begin confirming a recovery — not an analyst consensus.
The central target of $6.70 is the arithmetic mean of seven recent, individually verified analyst price targets, rounded from $6.67. At a latest price near $3.70, reaching $6.70 would require roughly 81% upside — a very large move.
Lead catalyst: Chemomab has secured alignment with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on a single Phase 3 registration trial for nebokitug in primary sclerosing cholangitis (PSC), a rare liver disease with no approved disease-modifying therapy. Strategic pivot: A planned merger with Scipher Medicine is expected to close by year-end 2026, extending nebokitug into an AI-powered, precision-medicine Phase 2 trial in rheumatoid arthritis (RA).